Can a modified interferon rein in early myelofibrosis?

NCT ID NCT06468033

Ongoing Disease control Sponsor: PharmaEssentia Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether ropeginterferon alfa-2b, a biologic drug, can help control blood cell counts and symptoms in adults with early or low-risk primary myelofibrosis, a bone marrow disorder. Participants receive either the drug or a placebo every two weeks for up to several months. The goal is to see if the drug can normalize blood counts, reduce symptom burden, and prevent progression to more advanced disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental biologic drug called ropeginterferon alfa-2b (P1101)
What this could lead to: If it works, this could offer a new treatment option to slow or control early-stage primary myelofibrosis, potentially delaying progression.
What could go wrong: This is a phase 3 trial, but the drug may not outperform placebo, and interferon-based therapies can cause flu-like symptoms, fatigue, or mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cellular phase chronic idiopathic myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOPROLIFERATIVE NEOPLASM PRIMARY MYELOFIBROSIS

Contacts and locations

Show contact details

Locations

Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
University of Yamanashi Hospital

Chūō, Yamanashi, 409-3898, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.